Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
rights to develop and commercialize opevesostat (previously MK-5684), an investigational CYP11A1 inhibitor for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Per a collaboration deal signed in 2022, Merck and Finnish pharmaceutical company, Orion Corporation currently have a co-development and co-commercialization agreement for opevesostat. The option exercise will convert the co-exclusive license into an exclusive global license for Merck. Opevesostat is an oral, non-steroidal inhibitor of CYP11A1, an enzyme that suppresses the production of steroid hormones, which play a key role in causing prostate cancer. Opevesostat is now being evaluated in two phase III studies for the treatment of certain patients with mCRPC. With the latest option exercise, Merck will also get exclusive rights to other candidates targeting CYP11A1 covered by the agreement. Merck's stock has risen 17.3% so far this year, underperforming an increase of 21
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients [Yahoo! Finance]Yahoo! Finance
- Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals [Yahoo! Finance]Yahoo! Finance
- Roche to Halt Lung Cancer Drug Study in Fresh Setback [BNN Bloomberg (Canada)]BNN Bloomberg
- Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly [Yahoo! Finance]Yahoo! Finance
- Evaxion Reinforces Milestone Timeline and Provides Shareholder Update [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 7/2/24 - Form 4
- 7/2/24 - Form 4
- 7/2/24 - Form 4
- MRK's page on the SEC website